GBT's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Global Blood Therapeutics's Forward Dividend Yield %
For the Biotechnology subindustry, Global Blood Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Blood Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Global Blood Therapeutics's Forward Dividend Yield % falls into.
Global Blood Therapeutics Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Global Blood Therapeutics (NAS:GBT) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Global Blood Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Global Blood Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Global Blood Therapeutics (Global Blood Therapeutics) Business Description
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GBT has been successfully added to your